Resources
21 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 2/10/2021 (updated 4/4/2024)
The Opioid Response Network is making available a new dental curriculum on SBIRT (screening, brief intervention and referral to treatment), an evidence-based approach to managing patients with or at risk of developing a substance use disorder (SUD).
The curriculum was developed for dentists by the ORN grant through a collaboration with the American Academy of Addiction Psychiatry and the Division on Substance Use Disorders, Columbia University Irving Medical Center/NYSPI.
Posted 12/23/2020 (updated 4/4/2024)
This technical package provides evidence of the effectiveness of strategies and approaches for supporting successful planning, design, implementation, and sustainability of syringe services programs (SSPs). It provides a broad framework for new and existing SSPs to ensure needs-based service delivery, reduce harms related to injection drug use, and link participants to services that support their health and wellness.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 10/28/2020 (updated 4/3/2024)
These sample Needs Assessments have been created by RCORP Planning grantees. Please note, these samples are from Planning II grantees and the required elements for the Planning III cohort Needs Assessments have changed. Please refer to the list of required elements for Planning III grantees in your RCORP Planning III Orientation Packet.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 9/1/2021 (updated 4/2/2024)
Posted 10/19/2020 (updated 3/29/2024)
The Providers Clinical Support System (PCSS) Mentoring Program support is recommended for clinicians who are contemplating or have recently begun prescribing MOUD and would like additional support. PCSS offers three tiers of service at no cost to the recipient: (1) a discussion forum, (2) the ability to submit a clinical question through the PCSS website, and (3) one-on-one mentoring.
Posted 9/18/2020 (updated 3/29/2024)
We have included information that will be relevant
to the broad range of HRSA RCORP-Planning grantees.
We encourage you to work through this packet section by
section, keeping in mind the timeline for final submission of
core grant deliverables.